Home LiteratureArticle Details
PMID: 10429676 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.

The Journal of experimental medicine ·Vol. 190 ·No. 1 ·1999-07-05 ·Pages 125-33

Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP

Abstract

We transduced BALB/c-derived C-26 colon carcinoma cells with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand (CD40L) genes to favor interaction of these cells with host dendritic cells (DCs) and, therefore, cross-priming. Cotransduced cells showed reduced tumorigenicity, and tumor take was followed by regression in some mice. In vivo tumors were heavily infiltrated with DCs that were isolated, phenotyped, and tested in vitro for stimulation of tumor-specific cytotoxic T lymphocytes (CTLs). BALB/c C-26 carcinoma cells express the endogenous murine leukemia virus (MuLV) env gene as a tumor-associated antigen. This antigen is shared among solid tumors of BALB/c and C57BL/6 mice and contains two epitopes, AH-1 and KSP, recognized in the context of major histocompatibility complex class I molecules H-2Ld and H-2K(b), respectively. DCs isolated from C-26/GM/CD40L tumors grown in (BALB/c x C57BL/6)F1 mice (H-2d x b) stimulated interferon gamma production by both anti-AH-1 and KSP CTLs, whereas tumor-infiltrating DCs (TIDCs) of BALB/c mice stimulated only anti-AH-1 CTLs. Furthermore, TIDCs primed naive mice for CTL activity as early as 2 d after injection into the footpad, whereas double-transduced tumor cells required at least 5 d for priming; this difference may reflect direct DC priming versus indirect tumor cell priming. Immunohistochemical staining indicated colocalization of DCs and apoptotic bodies in the tumors. These data indicate that DCs infiltrating tumors that produce GM-CSF and CD40L can capture cellular antigens, likely through uptake of apoptotic bodies, and mature in situ to a stage suitable for antigen presentation. Thus, tumor cell-based vaccines engineered to favor the interaction with host DCs can be considered.

MeSH Terms
Animals Antigens, Neoplasm/immunology,metabolism CD40 Ligand Colonic Neoplasms/immunology Dendritic Cells/immunology Female Flow Cytometry Granulocyte-Macrophage Colony-Stimulating Factor/genetics Membrane Glycoproteins/genetics Mice Mice, Inbred BALB C T-Lymphocytes, Cytotoxic/immunology Tumor Cells, Cultured
Chemicals
Antigens, Neoplasm Membrane Glycoproteins CD40 Ligand Granulocyte-Macrophage Colony-Stimulating Factor
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Chiodoni C
Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Paglia P
Stoppacciaro A
Rodolfo M
Parenza M
Colombo M P
References (43)
43 references, click to expand
  1. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
    Cancer Res. 1996 May 1;56(9):2191-8 PMID: 8616871
  2. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation.
    J Exp Med. 1999 Feb 15;189(4):611-4 PMID: 9989975
  3. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.
    J Exp Med. 1996 Aug 1;184(2):747-52 PMID: 8760829
  4. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.
    Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9730-5 PMID: 8790399
  5. Combined chemokine and cytokine gene transfer enhances antitumor immunity.
    Nat Med. 1996 Oct;2(10):1090-5 PMID: 8837606
  6. Human renal-cell carcinoma tissue contains dendritic cells.
    Int J Cancer. 1996 Sep 27;68(1):1-7 PMID: 8895531
  7. The best cytokine for the job.
    Nat Med. 1997 Feb;3(2):126 PMID: 9018223
  8. Constitutive class I-restricted exogenous presentation of self antigens in vivo.
    J Exp Med. 1996 Sep 1;184(3):923-30 PMID: 9064352
  9. Functions of CD40 on B cells, dendritic cells and other cells.
    Curr Opin Immunol. 1997 Jun;9(3):330-7 PMID: 9203418
  10. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help.
    J Exp Med. 1997 Jul 7;186(1):65-70 PMID: 9206998
  11. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines.
    Eur J Immunol. 1997 Sep;27(9):2375-82 PMID: 9341783
  12. Antitumor responses induced by transgenic expression of CD40 ligand.
    Hum Gene Ther. 1997 Nov 1;8(16):1935-43 PMID: 9382959
  13. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.
    Nature. 1998 Mar 5;392(6671):86-9 PMID: 9510252
  14. Dendritic cells and the control of immunity.
    Nature. 1998 Mar 19;392(6673):245-52 PMID: 9521319
  15. Chromosomal position and specific demethylation in enhancer sequences of germ line-transmitted retroviral genomes during mouse development.
    Mol Cell Biol. 1985 Sep;5(9):2212-20 PMID: 3837187
  16. Improved retroviral vectors for gene transfer and expression.
    Biotechniques. 1989 Oct;7(9):980-2, 984-6, 989-90 PMID: 2631796
  17. Tumor antigen presentation by murine epidermal cells.
    J Immunol. 1991 May 15;146(10):3656-61 PMID: 2026885
  18. Cytokines in context.
    J Cell Biol. 1991 Jun;113(5):981-6 PMID: 2040651
  19. The dendritic cell system and its role in immunogenicity.
    Annu Rev Immunol. 1991;9:271-96 PMID: 1910679
  20. Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours.
    Cancer Immunol Immunother. 1991;34(1):53-62 PMID: 1760812
  21. Anticancer role of dendritic cells (DC) in human and experimental cancers--a review.
    Anticancer Res. 1992 Mar-Apr;12(2):511-20 PMID: 1349798
  22. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43 PMID: 8097319
  23. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma.
    J Exp Med. 1993 Jul 1;178(1):151-61 PMID: 7686211
  24. Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes.
    J Immunol. 1994 Jan 1;152(1):106-16 PMID: 8254184
  25. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
    J Exp Med. 1994 Apr 1;179(4):1109-18 PMID: 8145033
  26. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors.
    Int J Cancer. 1994 May 1;57(3):440-7 PMID: 8169008
  27. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
    Science. 1994 May 13;264(5161):961-5 PMID: 7513904
  28. The CD40 antigen and its ligand.
    Annu Rev Immunol. 1994;12:881-922 PMID: 7516669
  29. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
    Cancer Res. 1994 Dec 1;54(23):6022-6 PMID: 7954438
  30. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    J Exp Med. 1996 Jan 1;183(1):317-22 PMID: 8551239
  31. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression.
    Nat Med. 1998 May;4(5):581-7 PMID: 9585232
  32. CD40 and CD154 in cell-mediated immunity.
    Annu Rev Immunol. 1998;16:111-35 PMID: 9597126
  33. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.
    Nature. 1998 Jun 4;393(6684):474-8 PMID: 9624003
  34. Help for cytotoxic-T-cell responses is mediated by CD40 signalling.
    Nature. 1998 Jun 4;393(6684):478-80 PMID: 9624004
  35. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.
    Nature. 1998 Jun 4;393(6684):480-3 PMID: 9624005
  36. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.
    J Exp Med. 1998 Jul 6;188(1):133-43 PMID: 9653090
  37. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world.
    Immunity. 1998 Jun;8(6):657-65 PMID: 9655479
  38. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites.
    J Exp Med. 1998 Jul 20;188(2):373-86 PMID: 9670049
  39. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.
    J Immunol. 1998 Aug 15;161(4):1901-7 PMID: 9712059
  40. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes.
    J Exp Med. 1998 Oct 5;188(7):1359-68 PMID: 9763615
  41. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells.
    J Exp Med. 1998 Dec 7;188(11):2163-73 PMID: 9841929
  42. Direct and indirect T cell priming by dendritic cell vaccines.
    Eur J Immunol. 1999 Jan;29(1):225-34 PMID: 9933104
  43. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.
    J Exp Med. 1996 Aug 1;184(2):741-6 PMID: 8760828
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1999-07-05
Pages
125-33
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2195555
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]